Allogene Therapeutics, Inc.
|Number of Estimates|
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA.
Market Cap: 3.8 Billion
Primary Exchange: NASDAQ
Shares Outstanding: 122 Million
Float: 47.6 Million
Sector: Health Technology
Longest drawdown: 286 trading days
From: 2018-11-06 To: 2019-12-09
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|